Previous Close | 1.8800 |
Open | 2.0600 |
Bid | 1.5200 x 800 |
Ask | 2.2500 x 3000 |
Day's Range | 1.8000 - 2.0600 |
52 Week Range | 1.0400 - 7.8600 |
Volume | |
Avg. Volume | 69,393 |
Market Cap | 21.782M |
Beta (5Y Monthly) | 0.87 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.8180 |
Earnings Date | Nov 16, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.50 |
SHELTON, CT / ACCESSWIRE / May 17, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, has filed the quarterly report for third quarter of its 2022 fiscal year with the Securities and Exchange Commission.
NanoViricides Inc (NYSE: NNVC) has initiated a program to screen its library of broad-spectrum antiviral nanoviricides against human Adenovirus 41 Type F (hAd41-F), believed to be strongly associated with the occurrence of severe hepatitis syndrome in some children. The company says its top priority remains to initiate human trials of its SARS-CoV-2 drug candidate NV-CoV-2 to combat COVID-19. NanoViricides expects filing a clinical trial application for COVID-19 to occur relatively soon, althoug
SHELTON, CT / ACCESSWIRE / May 16, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform reports that it has begun drug development to combat recent cases of severe pediatric hepatitis.